Eylea
(Aflibercept)ApprovedProtein / enzyme
RegeneronAflibercept is used to treat eye diseases caused by abnormal blood vessel growth, such as wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. It works by blocking signals that cause these harmful blood vessels to form and leak fluid into the eye.[2] Eylea is currently approved and in use across 70 indications[4].[1]
Eylea is one of 1114 small molecule programs targeting Hemangioma. It is currently in Approved.
70
Indications
331
Total Trials
23
Active Trials
1,113
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 69 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Tecentriq
RochePreclinical
DATROWAY
Daiichi SankyoPreclinical
Cymbalta
Alnylam PharmaceuticalsPreclinical
MS Contin
Merck & Co.Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Spravato
WWim Janssens
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Vit D
PPost Graduate Institute of Medical Education and Research, Chandigarh
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Macular Edema32 trials
Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema
Completed·—··NCT04018833·40 enrolled
Show 29 more trials
Age-Related Macular Degeneration27 trials
Show 24 more trials
Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration
Completed·—··NCT03313401·34 enrolled
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration
Completed·—·Phase 3·NCT02157077·90 enrolled
Metastatic Colorectal Cancer14 trials
Show 11 more trials
Adjuvant Aflibercept for Metastatic Colorectal Cancer
Terminated·—·Phase 2·NCT01669720·10 enrolled
Treatment9 trials
Show 6 more trials
Retinal Vein Occlusion6 trials
64 more indications
Macular Degeneration6 trials
Show 3 more trials
Efficacy and Safety6 trials
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
Completed·SSpanish Cooperative Group for the Treatment of Digestive Tumours (TTD)·Phase 2·NCT03279289·170 enrolled
Colorectal Cancer5 trials
Wet Age-Related Macular Degeneration5 trials
Neovascular AMD4 trials
Intravitreal Injections3 trials
Polypoidal choroidal vasculopathy3 trials
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT07365371·174 enrolled
Proliferative Diabetic Retinopathy3 trials
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Completed·—·Phase 2·NCT02863354·43 enrolled
Wet Macular Degeneration3 trials
Choroidal Neovascularization3 trials
Cataract2 trials
Monotherapy2 trials
Growth2 trials
nAMD2 trials
Vitrectomy2 trials
Diabetic Macular Oedema2 trials
Bevacizumab1 trial
Aflibercept and Bevacizumab for Diabetic Maculopathies
Recruiting·—·Phase 4·NCT06850571·102 enrolled
Corneal Neovascularization1 trial
Optical Coherence Tomography1 trial
Retinitis Pigmentosa1 trial
Diabetic Retinopathy1 trial
Vascular Disease1 trial
Prostate Cancer1 trial
Retinopathy of Prematurity1 trial
Lymphoma1 trial
Neoadjuvant Treatment1 trial
TED1 trial
Safety and Efficacy1 trial
Rectal Cancer1 trial
Liver Metastases1 trial
Randomized1 trial
Breast Cancer1 trial
Macular Edema1 trial
Randomized Controlled Trial1 trial
Locally-advanced Rectal Cancer1 trial
Histoplasmosis1 trial
Treatment for Presumed Ocular Histoplasmosis
Unknown status·—·Phase 1/2·NCT01790893·40 enrolled
Depot Formulation1 trial
Retinopathy1 trial
Intravitreal Aflibercept Injection for Radiation Retinopathy Trial
Unknown status·—·Phase 2·NCT03085784·40 enrolled
AMD1 trial
Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD
Withdrawn·—·N/A·NCT02457026
Aneurysm1 trial
Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms
Unknown status·—·Phase 1·NCT02403128·6 enrolled
ESS1 trial
Carcinoma1 trial
Chemotherapy1 trial
MPA1 trial
Eye Disorders1 trial
Intravenous1 trial
Vitreous Hemorrhage1 trial
Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage
Completed·—·Phase 4·NCT04153253·34 enrolled
Patients With Solid Tumors1 trial
Retinal Vasculitis1 trial
Advanced Solid Malignancies1 trial
Unspecified11 trials
Show 8 more trials
Regulatory
FDA Approval Timeline[5]
Nov 18, 2011
EYLEA
BLA BLA125387
Aug 18, 2023
EYLEA HD
BLA BLA761355
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Eylea drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Aflibercept. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]